Hong Kong, China

Chi-Wang MA

This inventor holds 1 USPTO granted patent. Top assignee: The University of Hong Kong. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chi-Wang MA. Retrieved from https://idiyas.com/inventor/chi-wang-ma-6th7lujm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Chi-Wang Ma in Beta-Lactam Compounds

Introduction

Chi-Wang Ma is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of microbiology through his innovative work on beta-lactam compounds. His research focuses on developing methods to detect carbapenemases and microbial carbapenem resistance, which are critical in combating antibiotic resistance.

Latest Patents

Chi-Wang Ma holds 1 patent for his invention titled "Beta-lactam compounds and methods of use thereof." This patent discloses beta-lactam compounds designed to detect carbapenemases or microbial carbapenem resistance. The compounds contain a chemical probe that, upon hydrolysis by carbapenemases, undergoes intramolecular rearrangement and releases the chemical probe. The detection of the released chemical probe indicates the presence of carbapenemases and microbial carbapenem resistance, providing a valuable tool for medical diagnostics.

Career Highlights

Chi-Wang Ma is affiliated with The University of Hong Kong, where he continues to advance research in the field of microbiology. His work has garnered attention for its potential impact on public health, particularly in the fight against antibiotic-resistant infections.

Conclusion

Chi-Wang Ma's innovative contributions to the development of beta-lactam compounds highlight the importance of research in addressing critical health challenges. His work exemplifies the role of inventors in advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…